Molecular basis of cytokine signalling - Theme and variations: Delivered on 8 July 2009 at the 34th FEBS Congress in Prague

FEBS Journal

Volumn 277, Issue 1, 2010, Pages 106-118

  Sebald, Walter ^a   Nickel, Joachim ^a   Zhang, Jin Li ^b   Mueller, Thomas D ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Bone morphogenetic proteins (BMP); Drug development; Interleukins; Molecular recognition; Receptor oligomers

Indexed keywords

ACTIVIN RECEPTOR IIA; ACTIVIN RECEPTOR IIB; AEROVANT; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR ANTAGONIST; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; OSTEOGENIC PROTEIN 1; PEGVISOMANT; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACROMEGALY; ALLERGIC ASTHMA; BINDING AFFINITY; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONFERENCE PAPER; CYSTINE KNOT MOTIF; HUMAN; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; MUSCULAR DYSTROPHY; MUTANT; NONHUMAN; OLIGOMERIZATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; CYTOKINES; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; MUTATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; STATIC ELECTRICITY;

EID: 73649146615     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07480.x     Document Type: Conference Paper

References (67)

1. Stroud RM Wells JA (2004) Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci STKE 2004, re7.
2. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, Smith SO Constantinescu SN (2003) Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 12, 1239 1250.
3. Rotzer D, Roth M, Lutz M, Lindemann D, Sebald W Knaus P (2001) Type III TGF-beta receptor-independent signalling of TGF-β2 via TβRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J 20, 480 490.
4. Chan FK (2007) Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37, 101 107.
5. Rodriguez-Frade J, Munoz LM Mellado M (2009) Chapter 5. Multiple approaches to the study of chemokine receptor homo- and heterodimerization. Methods Enzymol 461, 105 122.
6. Schlessinger J (1988) Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci 13, 443 447. (Pubitemid 18264445)
7. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR Wells JA (1991) Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254, 821 825. (Pubitemid 21917402)
8. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J et al. (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395, 511 516.
9. Mueller TD, Zhang JL, Sebald W Duschl A (2002) Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim Biophys Acta 1592, 237 250.
10. Reinemer P, Sebald W Duschl A (2000) The interleukin-4-receptor: from recognition mechanism to pharmacological target structure. Angew Chem Int Ed Engl 39, 2834 2846.
11. Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, Sebald W Mueller TD (2007) A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and Activin type IIB receptor. BMC Struct Biol 7, 6.
12. Allendorph GP, Vale WW Choe S (2006) Structure of the ternary signaling complex of a TGF-β superfamily member. Proc Natl Acad Sci USA 103, 7643 7648.
13. de Vos AM, Ultsch M Kossiakoff AA (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306 312.
14. Wang X, Lupardus P, Laporte SL Garcia KC (2009) Structural biology of shared cytokine receptors. Annu Rev Immunol 27, 29 60.
15. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD Garcia KC (2008) Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132, 259 272.
16. Hage T, Sebald W Reinemer P (1999) Crystal structure of the interleukin-4/receptor α chain complex reveals a mosaic binding interface. Cell 97, 271 281.
17. Letzelter F, Wang Y Sebald W (1998) The interleukin-4 site-2 epitope determining binding of the common receptor γ chain. Eur J Biochem 257, 11 20. (Pubitemid 28462575)
18. Kraich M, Klein M, Patino E, Harrer H, Nickel J, Sebald W Mueller TD (2006) A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor. BMC Biol 4, 13.
19. Wang X, Rickert M Garcia KC (2005) Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors. Science 310, 1159 1163.
20. Sebald W, Nickel J, Zhang JL Mueller TD (2004) Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem 385, 697 710.
21. Xia Y, Yu PB, Sidis Y, Beppu H, Bloch KD, Schneyer AL Lin HY (2007) Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem 282, 18129 18140.
22. Wiater E Vale W (2003) Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem 278, 7934 7941.
23. Wiater E, Harrison CA, Lewis KA, Gray PC Vale WW (2006) Identification of distinct inhibin and transforming growth factor β-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. J Biol Chem 281, 17011 17022.
24. Gilboa L, Nohe A, Geissendorfer T, Sebald W, Henis YI Knaus P (2000) Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell 11, 1023 1035.
25. Conte LL, Chothia C Janin J (1999) The atomic structure of protein-protein recognition sites. J Mol Biol 285, 2177 2198.
26. Clackson T Wells JA (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267, 383 386.
27. Cunningham BC Wells JA (1993) Comparison of a structural and a functional epitope. J Mol Biol 234, 554 563.
28. Zhang JL, Simeonowa I, Wang Y Sebald W (2002) The high-affinity interaction of human IL-4 and the receptor α chain is constituted by two independent binding clusters. J Mol Biol 315, 399 407.
29. Wang Y, Shen BJ Sebald W (1997) A mixed-charge pair in human interleukin 4 dominates high-affinity interaction with the receptor α chain. Proc Natl Acad Sci USA 94, 1657 1662.
30. Bogan AA Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol Biol 280, 1 9.
31. Demchuk E, Mueller T, Oschkinat H, Sebald W Wade RC (1994) Receptor binding properties of four-helix-bundle growth factors deduced from electrostatic analysis. Protein Sci 3, 920 935.
32. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, Woltring DM, Walker I, Ollis DL Young IG (2001) Structure of the complete extracellular domain of the common β subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell 104, 291 300.
33. Shi Y Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685 700.
34. Nickel J, Kotzsch A, Sebald W Mueller TD (2005) A single residue of GDF-5 defines binding specificity to BMP receptor IB. J Mol Biol 349, 933 947.
35. Seemann P, Schwappacher R, Kjaer KW, Krakow D, Lehmann K, Dawson K, Stricker S, Pohl J, Ploger F, Staub E et al. (2005) Activating and deactivating mutations in the receptor interaction site of GDF5 cause symphalangism or brachydactyly type A2. J Clin Invest 115, 2373 2381.
36. Kotzsch A, Nickel J, Seher A, Sebald W Muller TD (2009) Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity. EMBO J 28, 937 947.
37. Canalis E, Economides AN Gazzerro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24, 218 235.
38. Balemans W Van Hul W (2002) Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250, 231 250.
39. Garcia Abreu J, Coffinier C, Larrain J, Oelgeschlager M De Robertis EM (2002) Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene 287, 39 47.
40. De Robertis EM Kuroda H (2004) Dorsal-ventral patterning and neural induction in Xenopus embryos. Annu Rev Cell Dev Biol 20, 285 308.
41. Zhang JL, Huang Y, Qiu LY, Nickel J Sebald W (2007) von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms. J Biol Chem 282, 20002 20014.
42. Rentzsch F, Zhang J, Kramer C, Sebald W Hammerschmidt M (2006) Crossveinless 2 is an essential positive feedback regulator of Bmp signaling during zebrafish gastrulation. Development 133, 801 811.
43. Zhang JL, Qiu LY, Kotzsch A, Weidauer S, Patterson L, Hammerschmidt M, Sebald W Mueller TD (2008) Crystal structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding. Dev Cell 14, 739 750.
44. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Belmonte JC Choe S (2002) Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420, 636 642.
45. Macdougall IC (2008) Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 3, 200 207.
46. Roy-Ghanta S Orange JS (2009) Use of cytokine therapy in primary immunodeficiency. Clin Rev Allergy Immunol, doi :.
47. Bridwell KH, Anderson PA, Boden SD, Vaccaro AR Wang JC (2009) What's new in spine surgery. J Bone Joint Surg Am 91, 1822 1834.
48. Wurzler KK, Heisterkamp M, Bohm H, Kubler NR, Sebald W Reuther JF (2004) Mandibular reconstruction with autologous bone and osseoinductive implant in the Gottingen minipig. Mund Kiefer Gesichtschir 8, 75 82.
49. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED et al. (2008) A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 105, 7082 7087.
50. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH Sherman ML (2009) Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24, 744 752.
51. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J et al. (2005) Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 102, 18117 18122.
52. McPherron AC, Lawler AM Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387, 83 90.
53. Lee SJ McPherron AC (2001) Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98, 9306 9311.
54. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF Lee SJ (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350, 2682 2688.
55. Wenzel S, Wilbraham D, Fuller R, Getz EB Longphre M (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422 1431.
56. Higham CE Trainer PJ (2008) Growth hormone excess and the development of growth hormone receptor antagonists. Exp Physiol 93, 1157 1169.
57. Kruse N, Tony HP Sebald W (1992) Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J 11, 3237 3244.
58. Tony HP, Shen BJ, Reusch P Sebald W (1994) Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur J Biochem 225, 659 665.
59. Grunewald SM, Werthmann A, Schnarr B, Klein CE, Brocker EB, Mohrs M, Brombacher F, Sebald W Duschl A (1998) An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol 160, 4004 4009.
60. Berryman DE, Palmer AJ, Gosney ES, Swaminathan S, DeSantis D Kopchick JJ (2007) Discovery and uses of pegvisomant: a growth hormone antagonist. Endokrynol Pol 58, 322 329.
61. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK Wilson IA (1996) Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273, 464 471.
62. Arkin MR Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3, 301 317.
63. Erlanson DA, Wells JA Braisted AC (2004) Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct 33, 199 223.
64. Haldar D, Jiang H, Leger JM Huc I (2006) Interstrand interactions between side chains in a double-helical foldamer. Angew Chem Int Ed Engl 45, 5483 5486.
65. Cheng RP (2004) Beyond de novo protein design -de novo design of non-natural folded oligomers. Curr Opin Struct Biol 14, 512 520.
66. Wells JA McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001 1009.
67. Muller T, Sebald W Oschkinat H (1994) Antagonist design through forced electrostatic mismatch. Nat Struct Biol 1, 674 676.